- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Inhibikase taps commercial chief from Pfizer, Gilead to pave the way for PAH launch | 30 | FiercePharma | ||
| 19.08. | Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | 326 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.08. | Inhibikase Therapeutics GAAP EPS of -$0.11 | 1 | Seeking Alpha | ||
| 14.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | 175 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 30.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Inhibikase Therapeutics files $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | 1 | FierceBiotech | ||
| 27.03. | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 463 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
| 18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 227 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen | |
| 14.11.24 | Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | 241 | GlobeNewswire (Europe) | -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 189,60 | +0,53 % | AbbVie Reports Third-Quarter 2025 Financial Results | Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results... ► Artikel lesen | |
| TEVA | 17,800 | +0,28 % | Teva Recalls Over 580,000 Bottles Of Blood Pressure Drug Over Cancer Risk Concern | PETAH TIKVA (dpa-AFX) - Over half a million bottles of the blood pressure drug prazosin hydrochloride have been recalled by the U.S. Food and Drug Administration because of potential contamination... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 10,465 | -7,10 % | EyePoint Pharmaceuticals, Inc.: EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| ORGANIGRAM GLOBAL | 1,370 | -2,84 % | ORGANIGRAM GLOBAL INC. - 6-K, Report of foreign issuer | ||
| QUANTUM BIOPHARMA | 9,850 | +3,14 % | Quantum BioPharma Ltd. Provides Corporate Update | TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K9A) ("Quantum" or the "Company"), a biopharmaceutical company dedicated to building a portfolio... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 10,800 | -1,82 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| AMARIN | 14,400 | +1,41 % | Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down | ||
| NEKTAR THERAPEUTICS | 57,00 | +1,79 % | Nektar Therapeutics: Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting | SAN FRANCISCO, Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 121,20 | +1,51 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 | DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,618 | +2,02 % | SELLAS Life Sciences raises $31 million through warrant exercise | ||
| MADRIGAL PHARMACEUTICALS | 366,80 | +0,94 % | Madrigal Pharmaceuticals: +40% seit Kauftipp im August - und jetzt? | Nach einem rasanten Kursanstieg und einer beispiellosen Marktdynamik rund um das Lebermedikament Rezdiffra richtet sich der Blick der Anleger von Madrigal Pharmaceuticals auf die bevorstehenden Quartalsergebnisse.... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,502 | -8,39 % | XORTX Therapeutics Inc.: XORTX Announces Closing of US$1.1 Million Registered Direct Offering | CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 54,88 | +0,59 % | AKTIONÄR-Tipp BridgeBio erneut mit Kurssprung - Aktie bereits 100 Prozent im Plus | Bei der Aktie des US-Biotech-Unternehmens BridgeBio geht es weiter steil aufwärts. Bereits in den vergangenen Monaten hatte sich das Papier nach der Empfehlung als Jahrestipp in Ausgabe 52/2024 - 01/2025... ► Artikel lesen | |
| OPUS GENETICS | 1,976 | -0,30 % | Opus Genetics, Inc.: Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) | Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 28,000 | +2,19 % | Rigel Gears Up to Report Q3 Earnings: Here's What to Expect |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,68 % bei einem Aktienkurs von 1,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.